A Phase 2 interventional study of Ketamine in Depression, Anxiety and Low Vision, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Stanford University · Phase 2, Interventional, and Treatment
Among 77 studies in Depression by Stanford University — 15 open to participants now, 17 under way, none of them phase 3. Depression · Stanford University.
Among the 77 studies in Depression by Stanford University, this one is the 31st largest by planned enrollment of the 64 interventional ones that give a count, is the only one that started in 2027, is one of 7 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 77th registered.
8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.
Browse Depression studies →15 of the 77 studies in Depression by Stanford University are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 5–14
Stanford University · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 1,088 Depression studies recruiting now, 469 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 310 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3 · Phase 4 5
First in 1999; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 81 across 7,063 interventional studies indexed under Depression.
Median enrollment 40 across the 64 interventional studies, 87 across the 12 observational. Of the 53 that completed or were terminated, 17 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,170 studies on the registry; 433 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
9 of the studies in Depression by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06317636Stanford UniversityPropofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression | 2026-11 |
| NCT07188623Stanford UniversityVirtual Reality-Enhanced Behavioral Activation for Older Adults With Depression | 2026-12 |
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT06430853Stanford UniversityPsychobiological Interventions in Pregnancy | 2027-01-01 |
| NCT06373718Stanford UniversitySleep Mechanisms Of Regulating Emotions | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Depression by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label study is to evaluate the effects of a single intravenous infusion of ketamine on depression and anxiety in adults with low vision.
Inclusion Criteria for Participants with Low Vision:
Inclusion Criteria for Healthy Controls:
Exclusion Criteria for Participants with Low Vision and Healthy Controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with low vision, as determined by ophthalmology assessments
Drug: Ketamine
Healthy adults with normal vision and no psychiatric diagnosis
Drug: Ketamine
Single intravenous racemic ketamine hydrochloride, 0.5 mg/kg in 100 ml of normal saline, infused over 40 minutes with continuous monitoring of vital signs.
Also known as: Ketamine Hydrochloride
Change in depression symptom severity as measured by the Hamilton Depression Rating Scale 17 (HDRS-17)
Change in depression severity is measured by the Hamilton Depression Rating Scale 17 (HDRS-17). For the HDRS-17 the minimum units are 0 and Maximum units on the total scale are 52. The higher the number on the HDRS-17, the more severe the symptoms, a reduction means improvement in depression symptoms. Response is defined as ≥ 50% reduction in score from baseline.
Time frame: Baseline (pre-infusion) to 1 week (post-infusion)
Change in anxiety symptom severity as measured by the Hamilton Anxiety Rating Scale (HAM-A)
Change in anxiety severity is measured by the Hamilton Anxiety Rating Scale (HAM-A). For the HAM-A the minimum units are 0 and Maximum units on the total scale are 56. The higher the number on the HAM-A, the more severe the symptoms, a reduction means improvement in anxiety symptoms. Response is defined as ≥ 50% reduction in score from baseline.
Time frame: Baseline (pre-infusion) to 1 week (post-infusion)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 143 non-industry phase 2 interventional studies under Depression, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 24 months is below that.
Counting every sponsor, half of 196 studies reached it within 31 months; a quarter within 18 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.